2016
DOI: 10.1007/s11427-016-5034-5
|View full text |Cite
|
Sign up to set email alerts
|

Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 98 publications
0
6
0
Order By: Relevance
“…[10] CD56, a member of the immunoglobulin superfamily is a biomarker of Neural-Cell Adhesion Molecule and NK cells. [11] The positive expression rate of CD56 in skeletal muscle tumors and peripheral neurogenic tumors was significantly higher than that in smooth muscle tumors and other spindle cell tumors. [12]…”
Section: Discussionmentioning
confidence: 99%
“…[10] CD56, a member of the immunoglobulin superfamily is a biomarker of Neural-Cell Adhesion Molecule and NK cells. [11] The positive expression rate of CD56 in skeletal muscle tumors and peripheral neurogenic tumors was significantly higher than that in smooth muscle tumors and other spindle cell tumors. [12]…”
Section: Discussionmentioning
confidence: 99%
“…Studies in the field of adoptive T-cell therapy in cancer treatment are taking rapid steps around the world. More than 200 protocols were recorded only in December 2015 [16], around 40% of which were related to CAR T-cell therapy [17]. Surprisingly, about 65% of these CAR T-cell therapies were designed for the treatment of hematological malignancies by targeting CD19 as a common antigen involved in the pathogenesis of various B cell malignancies (more than 80%) [18].…”
Section: Clinical Trial History and Development Of Car T-cell Therapementioning
confidence: 99%
“…The selection and identification of an optimal surface target antigen is a critical procedure for the development of a safe and active CAR engineering (Luo et al, 2016;Siegler et al, 2017). Generally, the CAR extracellular antigen-recognition domain is a single-chain variable fragment (scFv) derived from the heavy-and light-chain variable regions of a tumorreactive monoclonal antibody.…”
Section: The Extracellular Antibody-binding Portion: Who Is Exercising Powermentioning
confidence: 99%